Nastorazepide

Nastorazepide (Z-360) 是一种选择性的口服 1,5-苯二氮卓衍生物胃泌素/胆囊收缩素 2 (CCK-2) 受体拮抗剂，具有潜在的抗肿瘤活性。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥2062.00

1650.00

- +
10mg

￥3162.00

2530.00

- +
50mg

￥11875.00

9500.00

- +
100mg

￥20300.00

16240.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

Nastorazepide (Z-360) is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Target:CCK-2in vitro: Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells. Check for active clinical trials or closed clinical trials using this agent. in vivo: Z-360 is a novel orally active CCK-2/gastrin receptor antagonist, significantly inhibits the growth of subcutaneous xenografts of human pancreatic tumor cells in mice, and that Z-360 combined with gemcitabine prolonged survival in a pancreatic carcinoma orthotopic xenograft mice.

参考文献:
[1]. Kato H, et al. CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells. Life Sci. 2011 Oct 24;89(17-18):603-8.